Additional file 1: of Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis

presents information about quality control of the data, SLE signatures, and significant results obtained: Sheet 1 shows information about datasets including their GEO identifiers, the SLE state, the cell type, and the microarray platform for each, number of control and case samples, PubMed identifier, and date of publication; Sheet 2 shows results of the quality control based on the percentage of missing values and the number of significant genes in each dataset of SLE; Sheet 3 shows the signatures of each dataset used to query on Lincscloud, significant genes sorted by fold change in each signature; and Sheet 4 shows the lists of drugs and knock-in and knockdown genes with similarity scores, median of similarity scores across datasets, and significance values (XLSX 182 kb)